Neostigmine
- Generic Name
- Neostigmine
- Brand Names
- Bloxiverz, Prevduo, Prostigmin
- Drug Type
- Small Molecule
- Chemical Formula
- C12H19N2O2
- CAS Number
- 59-99-4
- Unique Ingredient Identifier
- 3982TWQ96G
- Background
A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier.
- Indication
Neostigmine is used for the symptomatic treatment of myasthenia gravis by improving muscle tone.
- Associated Conditions
- Curarization therapy, Myasthenia Gravis, Neuromuscular Blockade, Postoperative Urinary Retention (POUR), Acute Colonic Pseudo-Obstruction, Post-operative intestinal atony
- Associated Therapies
- -
Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-15
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 182
- Registration Number
- NCT00473694
Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 84
- Registration Number
- NCT00451100
Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960)
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 198
- Registration Number
- NCT00451217
The Impact of an Epidural Ropivacaine-Neostigmine Injection for Perineal Analgesia at the End of Labor.
Not Applicable
- Conditions
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2006-12-05
- Target Recruit Count
- 60
- Registration Number
- NCT00407290
- Locations
- 🇧🇪
Cliniques Universitaires Saint Luc, Brussels, Brusssels, Belgium
The Early Reversibility of Rocuronium After Different Doses of Neostigmine
Phase 4
Completed
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 60
- Registration Number
- NCT00001520
- Locations
- 🇺🇸
Warren G. Magnuson Clinical Center (CC), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath